Estudio del uso terapéutico de derivados de Cannabis sativa (DCS) en el tratamiento de enfermedades de pequeños animales en algunas clínicas veterinarias de la ciudad Bogotá

Vista sencilla de ítem
dc.contributor.advisorLozano Alvarez, Maria Constanza
dc.contributor.advisorLópez Gutierrez, Jose Julian
dc.contributor.authorSamacá Roberto, Juan Esteban
dc.contributor.researchgroupInvestigaciones Toxicológicas
dc.coverage.cityBogotá
dc.date.accessioned2026-02-09T20:51:38Z
dc.date.available2026-02-09T20:51:38Z
dc.date.issued2025
dc.descriptionIlustraciones
dc.description.abstractEl objetivo de este trabajo fue caracterizar el uso terapéutico de DCS en caninos y felinos atendidos en siete clínicas veterinarias de Bogotá con diferentes enfoques, a partir de la información registrada en historias clínicas y encuestas aplicadas a médicos veterinarios. Se desarrolló un estudio observacional y descriptivo, en el que se analizaron historias clínicas de pacientes tratados con DCS, registrando variables demográficas, diagnósticos, formas farmacéuticas, posología, estrategias terapéuticas concomitantes y desenlaces clínicos. De manera complementaria, se recopiló información sobre la percepción profesional en torno a la eficacia y seguridad de estos productos. Los resultados mostraron una prevalencia de uso de DCS del 2,2%, prescritos en caninos (80%) y en felinos (20%). Las principales indicaciones terapéuticas estuvieron relacionadas con procesos de inflamación crónica, alteraciones neurológicas y trastornos de conducta; adicionalmente, en perros también fueron empleados como soporte oncológico y en procesos asociados a inflamaciones agudas. Estas indicaciones se relacionaron con diferentes diagnósticos, entre los que se destacaron enfermedades musculoesqueléticas, neoplasias y enfermedades inmunomediadas. La vía de administración más utilizada fue la oral, con concentraciones variables de CBD y esquemas de dosificación ajustados según especie y condición clínica. En general, los desenlaces clínicos fueron favorables, con mejoría sintomática en la mayoría de los casos; los eventos adversos reportados fueron leves y autolimitados. Las encuestas a médicos veterinarios reflejaron una percepción positiva sobre la eficacia y seguridad de los DCS, aunque también señalaron la necesidad de avanzar en la estandarización de protocolos de prescripción y seguimiento. (Texto tomado de la fuente)spa
dc.description.abstractThe therapeutic use of Cannabis sativa derivatives (CSD), particularly cannabidiol (CBD), has attracted growing interest in veterinary medicine due to its analgesic, anti-inflammatory, anxiolytic, and anticonvulsant properties. In Colombia, the regulatory framework has facilitated the incorporation of these compounds into veterinary clinical practice; however, scientific evidence regarding their application in companion animals remains limited. The aim of this study was to characterize the therapeutic use of CSD in dogs and cats treated at seven veterinary clinics in Bogotá with different approaches, based on information recorded in medical histories and surveys administered to veterinarians. An observational and descriptive study was conducted, analyzing medical records of patients treated with CSD, documenting demographic variables, diagnoses, pharmaceutical forms, dosage regimens, concomitant therapeutic strategies, and clinical outcomes. Additionally, information on professional perceptions regarding the efficacy and safety of these products was collected. The results showed a prevalence of CSD use of 2.2%, prescribed in dogs (80%) and cats (20%). The main therapeutic indications were related to chronic inflammatory processes, neurological disorders, and behavioral alterations; in dogs, they were also prescribed as oncological support and for conditions associated with acute inflammation. These indications were consistent with different diagnoses, most notably musculoskeletal diseases, neoplastic processes, and immune-mediated disorders. The oral route was the most frequently used, with variable CBD concentrations and dosage regimens adjusted according to species and clinical condition. Overall, clinical outcomes were favorable, with symptomatic improvement in most cases; reported adverse events were mild and self-limiting. Surveys of veterinarians reflected a positive perception of the efficacy and safety of CSD, while also highlighting the need for further standardization of prescription and follow-up protocols.eng
dc.description.degreelevelMaestría
dc.description.degreenameMagister en Ciencias Farmacología
dc.description.researchareaAplicaciones Farmacéuticas en Veterinaria
dc.format.extent147 páginas
dc.format.mimetypeapplication/pdf
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/89431
dc.language.isospa
dc.publisherUniversidad nacional de Colombia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.publisher.facultyFacultad de Ciencias
dc.publisher.placeBogotá, Colombia
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Farmacología
dc.relation.referencesAbuhasira, R., Shbiro, L., & Landschaft, Y. (2018). Medical use of cannabis and cannabinoids containing products – regulations in Europe and North America. Eur. J. Internal Med. Special Issue, 49, 2–6. https://doi.org/10.1016/j.ejim.2018.01.001.
dc.relation.referencesAllweiler, S. (2020). Types of Pain - Special Pet Topics. Merck Veterinary Manual. Retrieved from.
dc.relation.referencesAmerican Veterinary Medical Association. AVMA. (2025). Cannabis in Veterinary Medicine – Resources Report (Versión 4). https://www.avma.org/sites/default/files/2025-04/aph-cannabis-resources-report- v4-2025.pdf
dc.relation.referencesBardin, L., Lavarenne, J., Eschalier, A. (2000). Serotonin receptor subtypes involved in the spinal antinociceptive effect of 5-HT in rats. Pain 86, 11–18. https://doi.org/10.1016/s0304-3959(99)00307-3.
dc.relation.referencesBartner, L. R., McGrath, S., Rao, S., Hyatt, L. K., & Wittenburg, L. A. (2018). Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Canadian Journal of Veterinary Research, 82(3), 178-183. Bitencourt, R.M., Takahashi, R.N. (2018). Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials. Frontiers in Neuroscience, 12. https://doi.org/10.3389/fnins.2018.00502.
dc.relation.referencesBlessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836. https://doi.org/10.1007/s13311-015-0387-1
dc.relation.referencesBloomfield, M.A.P., Hindocha, C., Green, S.F., Wall, M.B., Lees, R., Petrilli, K., Costello, H., Ogunbiyi, M.O., Bossong, M.G., Freeman, T.P. (2019). The neuropsychopharmacology of cannabis: a review of human imaging studies. Pharmacol. Ther. 195, 132–161.
dc.relation.referencesBoehnke, K. F., Clauw, D. J., & Fitzcharles, M. A. (2022). Cannabinoids for chronic pain management: Clinical considerations and future directions. Pain Reports, 7(1), e963. https://doi.org/10.1097/PR9.0000000000000963
dc.relation.referencesBoggs, D.L., Nguyen, J.D., Morgenson, D., Taffe, M.A., Ranganathan, M. (2018). Clinical and preclinical evidence for functional interactions of Cannabidiol and Δ9- tetrahydrocannabinol. Neuropsychopharmacology 43, 142–154. https://doi.org/10.1038/npp.2017.209.
dc.relation.referencesBrandstrat. (2023). Estudio nacional de tenencia y cuidado de mascotas en Colombia. Brandstrat. https://www.brandstrat.com.co
dc.relation.referencesBritch, S.C., Wiley, J.L., Yu, Z., Clowers, B.H., Craft, R.M. (2017). Cannabidiol-Δ9- tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug and Alcohol Dependence, 175, 187–197. https://doi.org/10.1016/j.drugalcdep.2017.01.046.
dc.relation.referencesBuffington, C. A. T., Westropp, J. L., Chew, D. J., & Bolus, R. R. (2014). Clinical evaluation of multimodal environmental modification (MEMO) in the management of cats with idiopathic cystitis. Journal of Feline Medicine and Surgery, 16(7), 589-596. https://doi.org/10.1177/1098612X14539050
dc.relation.referencesBritish Small Animal Veterinary Association BSAVA Scientific Committee. (2020, diciembre 21). Use of cannabidiol (CBD) in dogs and cats. https://www.bsava.com/article/bsava-publishes-information-on-the-use-of- cannabidiol-cbd-in-dogs-and-cats/
dc.relation.referencesCarter, A. (2020). A north American history of Cannabis use in the treatment of epilepsy. J. Clin. Neurophysiol, 37, 35–38. https://doi.org/10.1097/WNP.0000000000000644.
dc.relation.referencesChalmers, D.T., Watson, S.J. (1991). Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ.
dc.relation.referencesCorsetti, S., Borruso, S., Malandrucco, L., Spallucci, V., Maragliano, L., Perino, R., D’Agostino, P., Natoli, E. (2021). Cannabis sativa L. may reduce aggressive behaviour towards humans in shelter dogs. Sci. Rep. 11, 2773. https://doi.org/10.1038/s41598- 021-82439-2.
dc.relation.referencesChiocchetti, R., De Silva, M., Aspidi, F., Cunha, R. Z., Gobbo, F., Tagliavia, C., & Morini, M. (2022). Distribution of cannabinoid receptors in keratinocytes of healthy dogs and dogs with atopic dermatitis. Frontiers in Veterinary Science, 9, 915896.
dc.relation.referencesDe Gregorio, D., McLaughlin, R.J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez- Canul, M., Aboud, M., Maione, S., Comai, S., Gobbi, G. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160, 136–150. https://doi.org/10.1097/j.pain.0000000000001386.
dc.relation.referencesDe Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias- Carri´on, O., Crippa, J.A., Zuardi, A.W., Nardi, A.E., Silva, A.C. (2014). Antidepressant- like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol. Disord. Drug Targets 13, 953–960. https://doi.org/10.2174/1871527313666140612114838.
dc.relation.referencesDeabold, K. A., Schwark, W. S., Wolf, L., & Wakshlag, J. J. (2019). Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals, 9(832).
dc.relation.referencesEsposito, G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M.R., Iuvone, T., Steardo, L. (2011). Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One 6. https://doi.org/10.1371/journal.pone.0028668.
dc.relation.referencesFerraz, C.R., Carvalho, T.T., Manchope, M.F., Artero, N.A., Rasquel-Oliveira, F.S., Fattori, V., Casagrande, R., Verri, W.A. (2020). Therapeutic potential of flavonoids in pain and inflammation: mechanisms of action, pre-clinical and clinical data, and pharmaceutical development. Molecules, 25. https://doi.org/10.3390/molecules25030762.
dc.relation.referencesFederación Cinológica Internacional. (2025, 24 de noviembre). Fédération Cynologique Internationale. Recuperado de https://fci.be/es/)
dc.relation.referencesFederación Internacional Felina (2025, 20 de julio). Home – Fédération Internationale Féline. Recuperado de https://fifeweb.org/).
dc.relation.referencesFitzgerald KT, Bronstein AC, Newquist KL. (2013). Marijuana poisoning. Topics in Companion Animal Medicine, 28(1), 8-12.
dc.relation.referencesFreeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019). How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci. Biobehav. Rev, 107, 696–712. https://doi.org/10.1016/j.neubiorev.2019,09,036.
dc.relation.referencesGamble, L.-J., Boesch, J.M., Frye, C.W., Schwark, W.S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E.S., Wakshlag, J.J. (2018). Pharmacokinetics, safety, and clinical efficacy of Cannabidiol treatment in osteoarthritic dogs. Frontiers in Veterinary Science, 5, 165. https://doi.org/10.3389/fvets.2018.00165.
dc.relation.referencesGenaro, K., Fabris, D., Arantes, A.L.F., Zuardi, A.W., Crippa, J.A.S., Prado, W.A. (2017). Cannabidiol is a potential therapeutic for the affective-motivational dimension of incision pain in rats. Frontiers in Pharmacology, 8. https://doi.org/10.3389/fphar.2017.00391.
dc.relation.referencesGesell FK, Zoerner AA, Brauer C, et al. (2013). Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder. BMC Veterinary Research, 9, 262.
dc.relation.referencesGiacoppo, S., Galuppo, M., Pollastro, F., Grassi, G., Bramanti, P., Mazzon, E. (2015). A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis. Daru, 23. https://doi.org/10.1186/s40199-015-0131-8.
dc.relation.referencesGreb, A., Puschner, B. (2018). Cannabinoid treats as adjunctive therapy for pets: gaps in our knowledge. Toxicol. Commun. 2, 10–14. https://doi.org/10.1080/24734306.2018.1434470.
dc.relation.referencesGrotenhermen, F. (2003). Consejos prácticos. En F. Grotenhermen, E. Russo, & R. Navarrete (Eds.), Cannabis and cannabinoides. Farmacología, toxicología y potencial terapéutico (pp. 91-96).
dc.relation.referencesGuardabassi, L., Prescott, J. F., & Schwarz, S. (2015). Antimicrobial Resistance in Bacteria from Livestock and Companion Animals. Wiley-Blackwell.
dc.relation.referencesHammerle, M., Horst, C., Levine, E., Overall, K., Radosta, L., Rafter-Ritchie, M., Yin, S. (2015). 2015 AAHA canine and feline behavior management guidelines*. J. Am. Anim. Hosp. Assoc. 51, 205–221. https://doi.org/10.5326/JAAHA-MS-6527.
dc.relation.referencesHarirforoosh, S., Asghar, W., Jamali, F. (2013). Adverse effects of nonsteroidal anti- inflammatory drugs: an update of gastrointestinal, cardiovascular, and renal complications. Journal of Pharmaceutical and Pharmaceutical Sciences, 16(5), 821– 847. https://doi.org/10.18433/j3vw2f.
dc.relation.referencesHartsel, J.A., Boyar, K., Pham, A., Silver, R.J., Makriyannis, A. (2019). Cannabis in veterinary medicine: Cannabinoid therapies for animals. In: Gupta, R.C., Srivastava, A., Lall, R. (Eds.), Nutraceuticals in Veterinary Medicine. Springer International Publishing, Cham, pp. 121–155. https://doi.org/10.1007/978-3-030-04624-8_10.
dc.relation.referencesHenshaw, F.R., Dewsbury, L.S., Lim, C.K., Steiner, G.Z. (2021). The effects of cannabinoids on pro- and anti-inflammatory cytokines: a systematic review of in vivo studies. Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2020.0105.
dc.relation.referencesHerkenham M, Lynn AB, Little MD, et al. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences, 87(5), 1932-1936.
dc.relation.referencesHill, K.P., Palastro, M.D., Johnson, B., Ditre, J.W. (2017). Cannabis and pain: a clinical review. Cannabis and Cannabinoid Research, 2(1), 96–104. https://doi.org/10.1089/can.2017.0017.
dc.relation.referencesHowlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A., Felder, C.C., Herkenham, M., Mackie, K., Martin, B.R., Mechoulam, R., Pertwee, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161–202. https://doi.org/10.1124/pr.54.2.161.
dc.relation.referencesInstituto Colombiano Agropecuario. (2021). Salud animal y productos farmacéuticos. ICA. https://www.ica.gov.co/
dc.relation.referencesInstituto Distrital de Protección y Bienestar Animal. (2023). Informe anual de adopciones y rescates. Alcaldía Mayor de Bogotá. https://www.animalesbog.gov.co
dc.relation.referencesJunta Internacional de Fiscalización de Estupefacientes (2019) informe correspondiente al 2019.
dc.relation.referencesKasten, C.R., Zhang, Y., Boehm, S.L. (2019). Acute cannabinoids produce robust anxietylike and locomotor effects in mice, but long-term consequences are age- and sexdependent. Frontiers in Behavioral Neuroscience, 13. https://doi.org/10.3389/fnbeh.2019.00032.
dc.relation.referencesKogan, L. R., Hellyer, P. W., & Robinson, N. G. (2017). Consumers' perceptions of hemp products for animals. Journal of the American Holistic Veterinary Medical Association, 42, 40-48.
dc.relation.referencesKogan, L., Hellyer, P., Downing, R. (2020). The use of Cannabidiol-rich hemp oil extract to treat canine osteoarthritis-related pain: a pilot study. Journal of the American Holistic Veterinary Medical Association, 58, 11.
dc.relation.referencesKogan, L.R., Hellyer, P.W., Silcox, S., Schoenfeld-Tacher, R. (2019). Canadian dog owners’ use and perceptions of cannabis products. Can. Vet. J. 60, 749–755.
dc.relation.referencesKulpa JE, Paulionis LJ, Eglit GM, Vaughn DM. (2021). Safety and tolerability of escalating cannabinoid doses in healthy cats. Journal of Feline Medicine and Surgery, 23(12), 1162-1171.
dc.relation.referencesLanda, L., Sulcova, A., & Gbelec, P. (2016). The use of cannabinoids in animals and therapeutic implications for veterinary medicine: A review. Veterinární Medicína, 61(3), 111-122.
dc.relation.referencesLesch, K.-P., Bengel, D., Heils, A., Sabol, S.Z., Greenberg, B.D., Petri, S., Benjamin, J., Müller, C.R., Hamer, D.H., Murphy, D.L. (1996). Association of Anxiety-Related Traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527–1531. https://doi.org/10.1126/science.274.5292.1527.
dc.relation.referencesLivingston, A. (2010). Pain and analgesia in domestic animals. In F. Cunningham, J. Elliott, P. Lees (Eds.), Comparative and Veterinary Pharmacology, Handbook of Experimental Pharmacology (pp. 159–189). Springer.
dc.relation.referencesLozano Ferruccio, A., & Sosa Ramírez, N. A. (2020). CannaVet [Tesis de maestría, Universidad EAN]. Universidad EAN.
dc.relation.referencesMackie, K. (2006). Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46, 101–122.
dc.relation.referencesMackie, K. (2008). Signaling via CNS cannabinoid receptors. Molecular and Cellular Endocrinology, 286(1-2 Suppl 1), S60-S65.
dc.relation.referencesMarcondes-Alves, L., Fattori, V., Borghi, S.M., Lourenco-Gonzalez, Y., Bussmann, A.J.C., Hirooka, E.Y., Casagrande, R., Verri, W.A., Arakawa, N.S. (2019). Kaurenoic acid extracted from Sphagneticola trilobata reduces acetaminophen-induced hepatotoxicity through inhibition of oxidative stress and pro-inflammatory cytokine production in mice. Natural Product Research, 33, 921–924. https://doi.org/10.1080/14786419.2017.1416372.
dc.relation.referencesMartin-Santos, R., Crippa, A.J., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M., Langohr, K., Farre, M., Zuardi, A.W., McGuire, P.K. (2012). Acute effects of a single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers. Curr. Pharm. Des. 18, 4966–4979. https://doi.org/10.2174/138161212802884780.
dc.relation.referencesMathews, K. A., Kronen, P. W., Lascelles, D., Nolan, A., Robertson, S., Steagall, P. V., Wright, B., & Yamashita, K. (2014). Guidelines for recognition, assessment and treatment of pain. Journal of Small Animal Practice, 55(6), E10-E68. https://doi.org/10.1111/jsap.12200
dc.relation.referencesMcGrath S, Bartner LR, Rao S, et al. (2019). Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, 254(11), 1301-1308.
dc.relation.referencesMcGrath, S., Bartner, L. R., Rao, S., Kogan, L. R., & Hellyer, P. W. (2018). A report of adverse effects associated with the administration of cannabidiol in healthy dogs. Journal of the American Holistic Veterinary Medical Association, 52, 34-38.
dc.relation.referencesMechoulam, R., Benshabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., ... & Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83- 90.
dc.relation.referencesMejía, S., Duerr, F.M., Griffenhagen, G., McGrath, S. (2021). Evaluation of the effect of Cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. Journal of the American Animal Hospital Association, 57, 81–90. https://doi.org/10.5326/JAAHA-MS-7119.
dc.relation.referencesMissouri Botanical Garden. (2013). Cannabis sativa L. Retrieved from http://www.tropicos.org/Name/21302042.
dc.relation.referencesMorena, M., Patel, S., Bains, J.S., Hill, M.N. (2016). Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacol 41, 80–102. https://doi.org/10.1038/npp.2015.166.
dc.relation.referencesMorris, E.M., Kitts-Morgan, S.E., Spangler, D.M., McLeod, K.R., Costa, J.H.C., Harmon, D.L. (2020). The impact of feeding Cannabidiol (CBD) containing treats on canine response to a noise-induced fear response test. Front. Vet. Sci. 7. https://doi.org/10.3389/fvets.2020.569565.
dc.relation.referencesMurataeva, N., Straiker, A., Mackie, K. (2014). Parsing the players: 2- arachidonoylglycerol synthesis and degradation in the CNS. Br. J. Pharmacol. 171, 1379–1391. https://doi.org/10.1111/bph.12411.
dc.relation.referencesNascimento Menezes, P.M., Valença Pereira, E.C., Gomes da Cruz Silva, M.E., da Silva, B.A.O., de Souza Duarte Filho, L.A.M., de Lima Araújo, T.C., Bezerra Lima, K.S., Silva, F.S., Rolim, L.A. (2019). Cannabis and cannabinoids on treatment of inflammation: a patent review. Recent Patents on Biotechnology, 13, 256–267.
dc.relation.referencesNdong, C., O’Donnell, D., Ahmad, S., Groblewski, T. (2011). Cloning and pharmacological characterization of the dog cannabinoid CB2 receptor. Eur. J. Pharmacol. 669, 24–31. https://doi.org/10.1016/j.ejphar.2011.08.002.
dc.relation.referencesOliveira, C. R., Lima, L., & González, F. H. D. (2020). Veterinary population and epidemiological aspects of companion animals in Latin America. Revista de Medicina Veterinaria, 41(2), 45-53.
dc.relation.referencesPagano, E., Capasso, R., Piscitelli, F., Romano, B., Parisi, O.A., Finizio, S., Lauritano, A., Marzo, V.D., Izzo, A.A., Borrelli, F. (2016). An orally active cannabis extract with high content in cannabidiol attenuates chemically induced intestinal inflammation and hypermotility in the mouse. Frontiers in Pharmacology, 7. https://doi.org/10.3389/fphar.2016.00341.
dc.relation.referencesPapagianni, E.P., Stevenson, C.W. (2019). Cannabinoid regulation of fear and anxiety: an update. Curr. Psychiatry Rep. 21.
dc.relation.referencesPereira-Bengoa V. 2018. La historia clínica y el consentimiento informado en medicina veterinaria en Colombia: generación de instrumentos y sus reglas de organización y manejo. Consejo Profesional de Medicina Veterinaria y Zootecnia de Colombia Bogotá. URL: https://consejoprofesionalmvz.gov.co/src/files/Informe-Historia-clinica-y- consentimiento-informado.pdf.
dc.relation.referencesPertwee, R.G. (2001). Cannabinoid receptors and pain. Prog. Neurobiol. 63, 569–611. https://doi.org/10.1016/S0301-0082(00)00031-9.
dc.relation.referencesPertwee, R.G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199–215. https://doi.org/10.1038/sj.bjp.0707442.
dc.relation.referencesPoetker, D.M., Reh, D.D. (2010). A comprehensive review of the adverse effects of systemic corticosteroids. In Otolaryngologic Clinics of North America, Complications in Sinus and Skull Base Surgery, 43, 753–768. https://doi.org/10.1016/j.otc.2010.04.003.
dc.relation.referencesRana, T., Behl, T., Sehgal, A., Mehta, V., Singh, S., Kumar, R., & Bungau, S. (2022). Integrating Endocannabinoid Signalling In Depression. Journal of Molecular Neuroscience, 71(10), 2022–2034. https://doi.org/10.1007/s12031-020-01774-7
dc.relation.referencesReddy, D. S., & Golub, V. M. (2016). The pharmacological basis of Cannabis therapy for epilepsy. J. Pharmacol. Exp. Ther, 357, 45–55. https://doi.org/10.1124/jpet.115.230151.
dc.relation.referencesRusso EB. (2016). Los medicamentos cannabinoides y la necesidad del método científico. Cannabinoids 2007;2(2):16-19.
dc.relation.referencesSánchez, J. (2023). Consumo de los cuidadores de mascotas del Valle de Aburrá, Colombia, antes, durante y después del aislamiento obligatorio por COVID-19. Revista de ciencias administrativas y sociales, Unal, 33(87), 11-26.
dc.relation.referencesSirignano, C.; De Vita, S.; Gargiulo, E.; Lucidi, M.; Visaggio, D.; Chini, M.G.; Lauro, G.; Chianese, G.; Visca, P.; Bifulco, G.; et al. (2023) Exploring the Potential of Phytocannabinoids Against Multidrug-Resistant Bacteria. Plants 2025, 14, 1901. https://doi.org/ 10.3390/plants14131901
dc.relation.referencesSchleicher, E.M., Ott, F.W., Müller, M., Silcher, B., Sichler, M.E., L¨ow, M.J., Wagner, J. M., Bouter, Y. (2019). Prolonged cannabidiol treatment lacks on detrimental effects on memory, motor performance and anxiety in C57BL/6J mice. Frontiers in Behavioral Neuroscience, 13. https://doi.org/10.3389/fnbeh.2019.00094.
dc.relation.referencesShallcross, J., H´amor, P., Bechard, A.R., Romano, M., Knackstedt, L., Schwendt, M. (2019). The divergent effects of cdppb and cannabidiol on fear extinction and anxiety in a predator scent stress model of ptsd in rats. Frontiers in Behavioral Neuroscience, 13.
dc.relation.referencesShannon, S., Lewis, N., Lee, H., Hughes, S. (2019). Cannabidiol in anxiety and sleep: a large case series. Perm J. 23. https://doi.org/10.7812/TPP/18-041.
dc.relation.referencesSherman, B.L., Mills, D.S. (2008). Canine anxieties and phobias: an update on separation anxiety and noise aversions. Vet. Clin. N. Am. 38, 1081–1106. https://doi.org/10.1016/j.cvsm.2008.04.012.
dc.relation.referencesSilver, R.J. (2019). The endocannabinoid system of animals. Animals 9, 686. https://doi.org/10.3390/ani9090686.
dc.relation.referencesTalavera, Juan O., Roy-García, Ivonne A., Pérez-Rodríguez, Marcela, Palacios-Cruz, Lino, & Rivas-Ruíz, Rodolfo. (2020). De vuelta a la clínica. Métodos II. Arquitectura de la investigación clínica. Interacción sujeto, maniobras y enfermedad a través del tiempo. Gaceta médica de México, 156(5), 438-446. Epub 27 de mayo de 2021.https://doi.org/10.24875/gmm.20000159
dc.relation.referencesTambaro, S., Bortolato, M. (2012). Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat. CNS Drug Discov. 7, 25–40.
dc.relation.referencesThompson GR, Rosenkrantz H, Schaeppi UH, Braude MC. (1973). Comparison of acute oral toxicity of cannabinoids in rats, dogs, and monkeys. Toxicology and Applied Pharmacology, 25(3), 363–372.
dc.relation.referencesTiira, K., Sulkama, S., Lohi, H. (2016). Prevalence, comorbidity, and behavioral variation in canine anxiety. J. Vet. Behav. 16, 36–44. https://doi.org/10.1016/j.jveb.2016.06.008.
dc.relation.referencesVaughn D, Kulpa J, Paulionis L. (2020). Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs. Frontiers in Veterinary Science, 7, 51.
dc.relation.referencesVail, D. M., Thamm, D. H., & Liptak, J. M. (Eds.). (2020). Withrow & MacEwen’s Small Animal Clinical Oncology (6ª ed.). Elsevier.
dc.relation.referencesVerrico, C.D., Wesson, S., Konduri, V., Hofferek, C.J., Vazquez-Perez, J., Blair, E., Dunner, K.J., Salimpour, P., Decker, W.K., Halpert, M.M. (2020). A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. PAIN, 161, 2191–2202. https://doi.org/10.1097/j.pain.0000000000001896.
dc.relation.referencesWhite, C.M. (2019). A review of human studies assessing Cannabidiol’s (CBD) therapeutic actions and potential. J. Clin. Pharmacol. 59, 923–934. https://doi.org/10.1002/jcph.1387.
dc.relation.referencesWord Health Organization (2002). review of cannabis and cannabis-related substances.https://www.who.int/teams/health-product-and-policy- standards/controlled-substances/who-review-of-cannabis-and-cannabis-related- substances
dc.relation.referencesZieba, J., Sinclair, D., Sebree, T., Bonn-Miller, M., Gutterman, D., Siegel, S., Karl, T. (2019). Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRPindependent mechanism. Pharmacol. Biochem. Behav. 181, 93–100. https://doi.org/10.1016/j.pbb.2019.05.002.
dc.relation.referencesZuurman, L., Roy, C., Schoemaker, R.C., Hazekamp, A., den Hartigh, J., Bender, J., Verpoorte, R., Pinquier, J.L., Cohen, A.F., van Gerven, J. (2008). Effect of intrapulmonary tetrahydrocannabinol administration in humans. J. Psychopharmacol. https://doi.org/10.1177/0269881108089581.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.licenseReconocimiento 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.armarcGatosspa
dc.subject.armarcPerrosspa
dc.subject.armarcMedicina para mascotasspa
dc.subject.armarcFarmacología veterinariaspa
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéutica
dc.subject.ddc630 - Agricultura y tecnologías relacionadas::636 - Producción animal
dc.subject.decsPharmaceutical Preparations
dc.subject.decsPreparaciones Farmacéuticasspa
dc.subject.decsUso de la Marihuana -- Tratamiento farmacológicospa
dc.subject.decsUso de la Marihuana -- Terapiaspa
dc.subject.decsMarijuana Use -- Therapyeng
dc.subject.decsMarijuana Use -- Drug therapyeng
dc.subject.lccCatseng
dc.subject.lccDogseng
dc.subject.lccPet medicineeng
dc.subject.lccVeterinary pharmacologyeng
dc.subject.proposalCannabis medicinalspa
dc.subject.proposalMedical cannabiseng
dc.subject.proposalCannabidiolspa
dc.subject.proposalMedicina veterinariaspa
dc.subject.proposalVeterinary medicineeng
dc.subject.proposalPerrosspa
dc.subject.proposalGatoseng
dc.subject.proposalDogseng
dc.subject.proposalCatseng
dc.titleEstudio del uso terapéutico de derivados de Cannabis sativa (DCS) en el tratamiento de enfermedades de pequeños animales en algunas clínicas veterinarias de la ciudad Bogotáspa
dc.title.translatedStudy of the therapeutic use of Cannabis sativa derivatives (CSD) in the treatment of diseases in small animals in some veterinary clinics in the city of Bogotáeng
dc.typeTrabajo de grado - Maestría
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dcterms.audience.professionaldevelopmentInvestigadores
dcterms.audience.professionaldevelopmentMaestros
dcterms.audience.professionaldevelopmentPúblico general
dcterms.audience.professionaldevelopmentEspecializada
dcterms.audience.professionaldevelopmentEstudiantes
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
ESTUDI~1.PDF
Tamaño:
2.85 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Ciencias - Farmacología
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
5.74 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Maestría en Ciencias - Farmacología